Knowledge and Attitudes Concerning Aducanumab Among Older Americans After FDA Approval for Treatment of Alzheimer Disease.
cross_sectional · Level IV
Where this comes from
- Record sourced from PubMed, PMID 35157058.
- Also identified by DOI 10.1001/jamanetworkopen.2021.48355 and PMC identifier 8845005.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
This survey study examines the understanding of aducanumab and attitudes toward its potential outcomes among older Americans after the drug's approval by the US Food and Drug Administration (FDA) for the treatment for Alzheimer disease.
Medical subject headings
- Alzheimer Disease
- Antibodies, Monoclonal, Humanized
- Health Knowledge, Attitudes, Practice
- Patient Acceptance of Health Care